The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: A comparative study with other commonly used antibodies

American Journal of Surgical Pathology

Volumn 21, Issue 12, 1997, Pages 1399-1408

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

44 3A6; B72.3; Ber EP4; Carcinoembryonic antigen; HBME 1; Immunohistochemistry; Leu M1; Lung adenocarcinoma; Mesothelioma; SM3; Thrombomodulin

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MONOCLONAL ANTIBODY; THROMBOMODULIN; TUMOR MARKER;

ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; PLEURA MESOTHELIOMA; PLEURA TUMOR;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; THROMBOMODULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0342762008     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199712000-00002     Document Type: Article

References (73)

1. Adams VI, Unni KK. Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study. Am J Clin Pathol 1984;82:15-23.
2. Ascoli V, Sealzo CC, Facciolo F, Mardi F. Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions. Acta Cytol 1995;39:613-22.
3. Ascol V, Scalzo CC, Taccogna S, Nardi F. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med 1995;119:1136-40.
4. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibody: thrombomodulin, OV 632 and HBMB-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 1996;29:209-15.
5. Battifora H, Kopinski MI. Distinction of mesothelioma from adenocarcinoma: an immunohistochemical approach. Cancer 1985;55:1679-85.
6. Bedrossian CWM, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistiy. Semin Diagn Pathol 1972;124-40.
7. Benjamin CJ, Ritchie AC. Histoiogical staining for the diagnosis of mesothelioma. Am J Med Technol 1982;48:905-8.
8. Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue: a light-microscopic, ultrasouctural, and immunocytochemical study. Am J Surg Pathol 1986;10:34-47.
9. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing milignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993;24:347-54.
10. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47:5476-82.
11. Cagle PT, Truong LD, Roggli VL, Greenberg SD. Immunohistochemical differentiatton of sarcomatoid mesotheliomas other spindle cell neoplasms. Am J Clin Pathol 1989;92:566-71.
12. Chenard-Neu MP, Bellocq JP, Maier A, Batzenschlager A. Mésothéliomes malins de la plévre: analyse de leurs aspects immunohistochemiques. Ann Pathol 1990;10:20-7.
13. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol 1987;18:67-74.
14. Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199-203.
15. Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:127-33.
16. Corson JM, Pinkus GS. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen. An immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol 1982;108:80-7.
17. Dardick I, Jabi M, McCaughey WTE, Deodhare S, van Nostrand AWP, Srigley JR. Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum. Ultrastruct Pathol 1987;11:503-33.
18. Dejmek A, Hjerpe A. Carcinoembryonic antigen-like reactivity in malignant mesothelioma: a comparison between different commercially available antibodies. Cancer 1994;73:464-9.
19. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis. APMIS 1994:102:255-64.
20. Dewar A, Valente M, Ring NP, Corrin B. Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: an ultrastructural and cytochemical comparison. J Pathol 1987;152:309-16.
21. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-46.
22. Ernst CS, Atkinson BF. Mucicarmine positivity in malignant mesothelioma. Lab Invest 1980;42:113-4.
23. Friemann I, Otto H, Müller KM. Immunohistochemische Befunde zur Differentialdiagnose primärer und sekundârer Pleuratumoren. Verh Dtsch Ges Pathol 1986;70:311-6.
24. Gaffey MJ, Mills SE, Swanson PE, Zarbo RJ, Shah AR, Wick MR. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 1992;16:593-9.
25. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. Highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tradem repeats. J Biol Chem 1988;263:12820-3.
26. Ghosh AK, Gatter KC, Dunnill MS, Mason DY. Immunohistologic staining of reactive mesothelium, mesotheliomm, and lung carcinoma with a panel of monoclonal antibodies. J Clin Pathol 1987;40:19-25.
27. Gibbs AR, Harach R, Wagner JC, Jasani B. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 1985;40:91-5.
28. Hammar SP, Bockus DE, Remington FL, Rohrbach KA. Mucinpositive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with pulmonary mucinproducing pulmonary adenocarcinoma. Ultrastruct Pathol 1996;20:293-325.
29. Holden J, Churg A. Immunohistocheimcal staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol 1984;8:277-9.
30. Hsu S-M, Huang LC, Hsu PL, et al. Biochemical and ultrastructural study of Leu-M1 antigen in Reed-Sternberg cells: comparison with granulocytes and interdigitating reticulum cells. J Natl Cancer Inst 1986;77:363-70.
31. Hsu S-M, Raine L, Fanger H. Use of avidin-biotin-peroxidise complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
32. Jasani B, Edwards RE, Thomas ND, Gibbs AR. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virchows Arch A Pathol Anat Histopathol 1985;406:441-8.
33. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850-7.
34. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J. Use of monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Cancer Res 1985;45:1894-1900.
35. Kawai T, Greenberg SD, Truong LD, Mattioli CA, Klima H, Titus JL. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung. Am J Pathol 1988;130:401-10.
36. Kwee WS, Veldhuizen RW, Golding RP, et al. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Virchows Arch A Pathol Anat Histopathol 1982;397:287-99.
37. Lafebvre MP, Rodriguez: F, Schlom J, Carney WP, Rabin H, Wolfe HJ. The application of a monoclonal antibody to the differentiation of benign and malignant mesothelial proliferations from adenocarcinomas (Abstract). Lab Invest 1985;52:38A.
38. Latza U, Niedobitek G. Schwarting R, Nekarda R, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990;43:213-9.
39. Lee I, Radosevich JA, Chejfec G, et al. Malignant mesotheliomas: improved differential diagnosis from lung adenocarcinomas using monoclonal antibody 44-3A6 and 624A12. Am J Pathol 1986;123:497-507.
40. Leong AS-Y, Vernon-Roberts E. The immunohistochemistry of malignant mesothelioma. Pathol Annu 1994;29:157-79.
41. Lucas JG, Tuttle SE. Diagnostic histochemical and immnunohistochemical studies in malignant mesothelioma. J Surg Oncol 1987;35:30-4.
42. Maguire B, Whitetaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 1994;10:130-4.
43. Marshall RJ, Herbert A, Braye SG, Jones DB. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium. J Clin Pathol 1984;37:1215-21.
44. Maruyama I, Bell C, Majerus P. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncitiotrophoblasts of human placenta. J Cell Biol 1985;101:363-71.
45. McCaughey WTE, Colby TV, Battifora H, et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel. Mod Pathol 1991;4:342-53.
46. Miettinen M, Kovatich AJ. HBMB-1: a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft tissue and bone tumors, Appl Immunohistochem 1995;3:115-22.
47. Moch H, Oberholzer H, Dalquen N, Wegmann W, Gudat F. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I. Immunohistochemical findings. Virchows Arch A Pathol Anat Histopathol 1993;423:19-27.
48. a and anti-Tn antibodies. Hum Pathol 1989;20:53-7.
49. Nuti M, Teramoto YA, Mariani-Costantini R, Hand PH, Colcher D, Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary circinoma cell populations. Int J Cancer 1982;29:539-45.
50. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma. Am J Surg Pathol 1989;13:276-91.
51. Ordóñez NG, Mackay B. The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anat Pathol 1996;3:273-93.
52. Pfaltz M, Odermatt B, Christen B, Rüttner JR. Immunohistochemistry in the diagnosis of malignant mesothelioma. Virchows Arch A Pathol Anat Histopathol 1987;411:387-43.
53. Pileri S, Rivano MT, Mancini AM. Immunohistochemical characterization of mesotheliomas. Appl Pathol 1983;1:348-50.
54. Radosevich JA, Ma Y, Lee I, Salwen H, Gould VE, Rosen ST. Monoclonal antibody 44-3A6 as a probe for a novel antigen found in human lung carcinomas with glandular differentiation. Cancer Res 1985;45:5808-12.
55. Russo J, Russo IH. Immunocytochemical markers in breast cancer. In: DeLellis RA, ed. Advances in Immunohistochemistry. New York: Raven Press, 1988:431-75.
56. Said JW, Nash G, Tepper G, Banks-Schlegel S. Keratin proteins and carcinoembryonic antigen in lung carcinoma: an immunoperoxidase study of 54 cases, with ultrastructural correlations. Hum Pathol 1983;14:70-6.
57. Savera AT, Raju U, Linden MD. Mesothelioma vs. adenocarcinoma: diagnostic utility of HBME-1 (Abstract). Lab Invest 1996;74:162A.
58. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: an immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986;123:212-9.
59. Sheibani K, Shin SS, Kezirian J, Weiss LM. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991;15:779-84.
60. Sloane JP, Ormered MG. Distribution of epithelial membrane antigen in normal and neoplastic tissue and its value in diagnostic tumor pathology. Cancer 1981;47:1786-95.
61. SooHoo WEJ, Ordóñez NG. Expression of the core protein of polymorphic epithelial mucin as detected by SM-3 antibody in pulmonary adenocarcinoma and pleural malignant mesothelioma: United States and Canadian Academy of Pathology, 81st annual meeting, Atlanta, Georgia, March 14-20, 1992. Lab Invest 1992;66:116A.
62. Spagnolo DV, Whitaker D, Carrello S, Radosevich JA, Rosen ST, Gould VE. The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma. Am J Clin Pathol 1991;95:322-9.
63. Strickler JG, Herndier BG, Rouse RV. Immunohistochemical staining in malignant mesothelioroas. Am J Clin Pathol 1987;88:610-4.
64. Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986;122:252-60.
65. Taylor-Papadimitriou J, Gendler SJ. Molecular aspects of mucins. Cancer Rev 1988;11/12:11-24.
66. Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986;76:995-1006.
67. Vortmeyer AO, Preuss J, Pidberg B-C, Kastendieck H, Schröder S. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas: a clinicomorphological study of 158 cases. Anticancer Res 1991;11:889-94.
68. Wang N, Huang S, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers. Cancer 1979;44:937-43.
69. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma: periodic acid-Schiff. monoclonal antibodies B72.3, and Leu M1. Am J Pathol 1988;133:30-8.
70. Whitaker D, Sterrett GF, Shilkin KB. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma. Pathology 1982;14:255-8.
71. Wick MR, Loy T, Mills SE, Legier JE, Manifel JC. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990;21:759-66.
72. Wick MR, Mills SE, Swanson PE. Expression of "myelomonocytic" antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol 1990;94:18-26.
73. Wirth PR, Legier J, Wright GL. Immunohistochemical evaluation of seven antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991;67:655-62.